Evolution Research Group (“ERG”), has acquired Clinical Pharmacology of Miami, LLC (“CPMI”), a clinical investigative site conducting research protocols for pharmaceutical/biotech companies and a leader in specialty population Phase I trials. With this acquisition, ERG has now completed three strategic add-on acquisitions since DFW’s initial investment in April 2014, and continues to establish itself as the leading clinical trials provider in the Central Nervous System (“CNS”) space, with an expanding presence in other specialty populations, and with a consistent focus on compliance and quality.

    Lori Wright, Evolution Research Group’s CEO, commented, “The addition of CPMI’s highly experienced, quality-driven team and unique early phase capabilities complements ERG’s existing service offering on many levels. Importantly, our clients have come to rely on our expertise not only for the execution of their critical path studies in highly specialized populations in the field of neuroscience, but also for assistance in study design and crucial decision making processes along the path of a compound’s development. With the addition of CPMI, clients now further benefit from a single point of contact at ERG for all of their early phase needs through to pharmacology trials typically conducted later in the development cycle as well.”

    The acquisition was completed with additional debt financing from ERG’s existing lenders, Business Development Corporation of America and Babson Capital Management.

    This is a unique website which will require a more modern browser to work! Please upgrade today!